Stifel analyst Stephen Willey reiterated a Buy rating and $47.00 price target on Bicara Therapeutics Inc (NASDAQ: BCAX).The analyst said ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE